The manufacturer's submission The manufacturer's submission The Appraisal Committee (appendix A) considered evidence submitted by the manufacturer of golimumab and a review of this submission by the Evidence Review Group (ERG; appendix B).
3.1
The main clinical effectiveness data were derived from a single phase III randomised controlled trial (RCT) -GO-REVEAL. The trial compared golimumab with placebo for the treatment of active and progressive psoriatic arthritis in people who had symptoms despite the use of current or previous DMARDs or non-steroidal anti-inflammatory drugs. Of the 405 trial participants, 113 were randomised to placebo, 146 were randomised to a 50 mg dose of golimumab and 146 were randomised to a 100 mg dose of golimumab.
Randomisation was maintained for 24 weeks. Upward titration was allowed at week 16, such that the participants in the placebo group could switch to 50 mg golimumab and those in the 50 mg golimumab group could have their dose increased to 100 mg if their disease had failed to respond. In the placebo group 50% of participants crossed over to golimumab 50 mg treatment and in the golimumab 50 mg group 20% crossed over to golimumab 100 mg treatment.
Outcomes were assessed at 14 and 24 weeks.
3.2
The primary outcomes in GO-REVEAL were American of Rheumatology (ACR) 20 response at week 14 and the change from baseline in the psoriatic arthritis modified van der Heijde-Sharp (vdH-S) score at week 24. Secondary outcomes included ACR 20 response at week 24, Psoriatic Arthritis Response Criteria (PsARC) response at weeks 14 and 24, and Psoriasis Area and Severity Index (PASI) 75 improvement at week 14 in participants with psoriasis that affected 3% or more of their body surface area at baseline. Physical functional status was measured by Health Assessment Questionnaire (HAQ) score at week 24. Health-related quality of life was measured by the Short Form 36
Health Survey (SF-36) at week 14. 3.3 The week 14 results of GO-REVEAL indicated that, compared with placebo, golimumab showed a statistically significant improvement in joint disease. An ACR 20 response was seen in 50.7% of participants in the 50 mg treatment arm compared with 8.8% in the placebo arm (relative risk [RR] 5.727, 95% confidence interval [CI] 3.24 to 10.56). A PsARC response was seen in 73.3% of participants in the 50 mg treatment arm compared with 21.2% in the placebo arm (RR 3.451, 95% CI 2.46 to 4.87) . Golimumab also showed a statistically significant improvement in skin disease as measured by PASI 75 at both 14 and 24 weeks. A PASI 75 response was seen in 40.4% of participants in the 50 mg treatment arm compared with 2.5% in the placebo arm (RR 15.945, 95% CI 4.62 to 59.11) at 14 weeks, and in 55.9% of participants in the 50 mg treatment arm compared with 1.4% in the placebo arm (RR 40.794, 95% CI 7.86 to 232.88) at 24 weeks. There was also a statistically significant improvement in functional status (HAQ) at 24 weeks. A mean HAQ score change from baseline of 0.33 (standard deviation [SD] 0.55, p < 0.001) was observed in the golimumab 50 mg arm compared with −0.01 (SD 0.49) in the placebo arm. Data on HAQ score change from baseline were not available for the 14-week time point. 3.4 The manufacturer reported that golimumab 50 mg produced a statistically significant reduction from baseline in vdH-S score of 0.16 (p = 0.01) at 24 weeks compared with placebo. The reduction from baseline in vdH-S score was not statistically significant in the golimumab 100 mg group (p = 0.09). The manufacturer did not report vdH-S scores at the 14 week time point. 3.5 The Evidence Review Group (ERG) reported that the main limitation of the efficacy evaluation of golimumab was that the analyses of efficacy outcomes were restricted to the GO-REVEAL trial, which had a limited sample size and was of limited duration (see section 3.1).
3.6
The manufacturer stated that the most frequently reported adverse events associated with golimumab therapy were infections and infestations, including upper respiratory tract infections and nasopharyngitis. The manufacturer reported that the safety profile of golimumab was comparable to that of the other TNF inhibitors adalimumab, etanercept and infliximab.
3.7
The ERG reported concerns about the adverse event data presented for golimumab. It noted that no long-term adverse event data had been presented, and that in its original submission the manufacturer had not included adverse event data on golimumab from controlled studies of its use in other conditions such as rheumatoid arthritis or ankylosing spondylitis. The ERG reported that the manufacturer's conclusion that golimumab has a safety profile comparable to that of the other TNF inhibitors may be premature. 3.8 Following consultation on the Appraisal Consultation Document, the manufacturer submitted evidence on the long-term safety of golimumab. These data included 104-week results from the GO-REVEAL extension study in addition to 52-and 104-week safety data in trial participants with psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis who had received treatment with golimumab across all of the original phase III studies. These data were marked as confidential and therefore cannot be reported. 3.9 In the absence of head-to-head comparisons between golimumab and the other TNF inhibitors, the manufacturer conducted a mixed treatment comparison.
The mixed treatment comparison included seven trials: the GO-REVEAL trial The trials included in the mixed treatment comparison were similar in terms of joint disease severity at baseline (for example, mean tender joint count and mean swollen joint count). There were differences, however, in the proportions of trial participants who could be evaluated for psoriasis endpoints at baseline.
Most participants had received treatment with one prior DMARD, although no trial specified non-response to at least two DMARDs.
3.11
The outcomes included in the mixed treatment comparison analyses were PsARC response, change in HAQ score given PsARC response to treatment, change in HAQ score given no PsARC response, and change in PASI in people with psoriasis that affected 3% or more of their body surface area at baseline.
The manufacturer selected absolute changes as the main outcomes, stating that these were the most appropriate outcomes for economic modelling. No analysis of the ACR outcomes was included in the mixed treatment comparison.
3.12
The results of the mixed treatment comparison indicated that of the four TNF inhibitors, golimumab was associated with the third highest PsARC response and absolute change in PASI from baseline. Of the four TNF inhibitors, golimumab had the lowest HAQ score change from baseline, both in people whose disease responded to treatment based on PsARC score and in those whose disease did not respond. The numerical values for each outcome derived from the mixed treatment comparison were marked as confidential and Golimumab for the treatment of psoriatic arthritis (TA220) therefore cannot be reported.
3.13
The ERG reported that the network of trials included in the mixed treatment comparison was appropriately constructed, but that there were differences among the trial populations in disease severity and number of previously tried DMARDs (with many participants having received only one previous DMARD).
The ERG commented that the trial populations were not precisely representative of the population with active and progressive psoriatic arthritis for whom TNF inhibitors are recommended in current British Society for Rheumatology guidelines and in Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (NICE technology appraisal guidance 199
[TA199]).
3.14
The manufacturer developed its own economic evaluation, which comprised a patient cohort model. The model compared the effects of treatment with golimumab (50 mg) in adults with active and progressive psoriatic arthritis whose disease had responded inadequately to DMARDs with the effects of treatment with infliximab, adalimumab and etanercept and with palliative care.
All people entered the model with the same baseline characteristics as participants in the GO-REVEAL trial and left the model at death, irrespective of the treatment regimen. The model used a 12-week cycle for the first two cycles and annual cycles thereafter. The model captured response to treatment using HAQ score (conditional on PsARC response) as the arthritis measure and PASI score as the psoriasis measure. If there was no response to treatment at 12 weeks (according to PsARC), treatment was discontinued. The price year used for costs was not reported in the manufacturer's submission. Costs and benefits were discounted at 3.5% per annum over 40 years.
3.15
The manufacturer reported that estimates of treatment effectivenessincluding PsARC response, HAQ score changes from baseline for people whose disease had responded to treatment according to PsARC at 12 weeks, HAQ score changes from baseline for those whose disease had not responded to treatment according to PsARC at 12 weeks, and PASI change from baseline in people with measurable psoriasis -were derived from the mixed treatment comparison.
3.16
The model assumed that people who continue treatment with a TNF inhibitor maintain their initial improvement in HAQ score. The same ongoing rate of Golimumab for the treatment of psoriatic arthritis (TA220) withdrawal from treatment was used for all the TNF inhibitors (16.5% per annum) and represented withdrawal because of treatment failure or adverse events.
3.17
The manufacturer combined data from IMPACT2 (a study of infliximab) and GO-REVEAL using the 'Gray' algorithm to estimate utility values. The Gray algorithm converts Short Form 36 (SF-36) data to EuroQol (EQ-5D) estimates and then to utilities. The disutility of adverse events was not modelled.
3.18
The manufacturer reported that resource use associated with treatment, administration and monitoring of infliximab, etanercept and adalimumab was taken from the Assessment Group's model for TA199. In the patient access scheme (as described in section 2.4) the manufacturer provides the 100 mg dose of golimumab at the same cost as the 50 mg dose. Therefore, only the cost of the 50 mg dose of golimumab (£774.58) was included in the model. The model contained an additional 4 hours of staff nurse costs for training people to selfadminister subcutaneous TNF inhibitors. The costs of infliximab were initially calculated on the assumption that vial sharing was allowed (using an average of 3.5 vials per infusion, although this assumption was later removed following a request for clarification from the ERG). The costs associated with adverse events were not included.
3.19
The manufacturer revised its original base-case estimates in response to a request from the ERG for clarification about the way utilities were calculated and for the removal of the infliximab vial sharing assumption. The revised basecase results produced total costs, total quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs, pairwise comparisons with palliative care) as follows: The ERG reported that the manufacturer had not provided an incremental analysis in which dominated and extendedly dominated options were excluded.
An option is 'dominated' if there is another option that is less costly and more effective. An option is 'extendedly dominated' when its ICER is higher than that of the next, more effective, option when compared with a common baseline (that is, it is dominated by a combination of two other alternatives). The ERG The ERG commented that the model structure was reasonable. The ERG stated that the inclusion of costs to cover time for training in self-injection may have been unnecessary, but reported that all other included costs were appropriate.
The ERG considered that it may have been appropriate to account for the possibility of dose escalation to 100 mg (as per the marketing authorisation; see section 2.3). The ERG reported that the subgroup analyses were appropriate.
3.23
Full details of all the evidence are in the manufacturer's submission and the ERG report.
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Page 12 The Committee discussed the 100 mg dose of golimumab, which may be considered for people who weigh more than 100 kg and whose psoriatic arthritis has not responded after three or four doses of golimumab (as stated in the SPC). It noted that neither the 100 mg arm nor dose escalation to 100 mg in the 50 mg arm in the GO-REVEAL trial was limited to people who weighed more than 100 kg, and therefore the trial population did not reflect the population in the marketing authorisation for the 100 mg dose. The Committee heard from clinical specialists that they would be more likely to select a different TNF inhibitor than to increase the dose if the 50 mg dose of golimumab failed to produce a response. The Committee concluded that it was uncertain of the extent to which the 100 mg dose would be used in clinical practice.
4.7
The Committee noted that there had been no head-to-head trials of golimumab and any of the other TNF inhibitors, and that, as a result, the manufacturer had however, that this difference may be due to differences in the trial populations, as reflected by the respective changes from baseline with placebo. The
Committee also understood that the absolute differences between the two changes from baseline were small. Although the evidence suggested that golimumab may be less effective in its anti-arthritic activity (based on the HAQ score results from the mixed treatment comparison and the data for radiographic progression), on balance the Committee concluded that the evidence was not robust enough to confirm clinically important differences in the effectiveness of golimumab compared with the other TNF inhibitors.
4.10
The Committee considered the evidence on the adverse event rates associated with the use of golimumab. It noted a number of reported 'serious' adverse events, but understood that GO-REVEAL was not powered to detect statistically significant differences in adverse event outcomes. The Committee considered the additional evidence submitted by the manufacturer on the longterm adverse event data for golimumab in people with psoriatic arthritis, and also for people with rheumatoid arthritis and ankylosing spondylitis. It concluded that although there remains uncertainty about golimumab's longterm adverse event profile, it had not been shown to be different from that of other TNF inhibitors.
4.11
The Committee considered the economic model presented by the manufacturer.
The Committee noted that the model assumed people continuing on therapy maintained their initial improvement in HAQ score. The Committee considered the utility estimates incorporated in the model, and noted that the utility formula was derived from the HAQ score change and the PASI response. The HAQ score change had a greater effect on utility than the PASI response did, indicating that the calculated utility benefit was driven more by the reduction in joint symptoms than the reduction in skin disease. The Committee concluded that this was appropriate (see section 4.9).
4.12
The Committee considered the results of the manufacturer's base-case analysis, which compared each of the TNF inhibitors (including golimumab) with palliative care. The Committee heard from the ERG that the pair-wise comparisons with palliative care needed to be reworked into an incremental analysis comparing each treatment with the next most effective alternative. The ERG re-presented these results. The Committee was aware that the acquisition costs of adalimumab, etanercept and golimumab (50 mg) were similar, and that
Golimumab for the treatment of psoriatic arthritis (TA220) the acquisition cost of infliximab was dependent on the person's weight and the amount of the drug required, with additional administration costs for infliximab (related to intravenous infusion). The Committee noted that all alternatives to etanercept were either dominated (infliximab was more expensive but no better than etanercept) or extendedly dominated (adalimumab and golimumab were, in effect, less cost effective than etanercept; see section 3.20). The Committee agreed that golimumab was, in effect, less cost effective than etanercept.
4.13
The Committee was aware, however, that TA199 recommends adalimumab and infliximab alongside etanercept. The Committee therefore also considered whether golimumab was at least as cost effective as adalimumab and infliximab.
The Committee was aware that in the incremental analysis, both adalimumab and golimumab were extendedly dominated by etanercept. However, the Committee noted that the pairwise ICER of golimumab compared with adalimumab alone would be approximately £24,000 per QALY gained. The
Committee similarly noted that the pairwise ICER for golimumab compared with infliximab would be approximately £45,000, aware that in this instance the ICER would represent a 'savings per QALY lost', as golimumab was associated with both lower costs and fewer QALYs compared with infliximab (see section 3.19). Given the weaknesses of the evidence suggesting lesser clinical effectiveness of golimumab compared with the other TNF inhibitors, and the estimates of golimumab's cost effectiveness compared with adalimumab and infliximab, the Committee concluded that the 50 mg dose of golimumab was acceptable when the criteria in TA199 are met; that is, the person has peripheral arthritis with three or more tender joints and three or more swollen joints, and the psoriatic arthritis has not responded to adequate trials of at least two standard disease-modifying antirheumatic drugs (DMARDs), administered either individually or in combination.
4.14
The Committee considered the 100 mg dose of golimumab. The Committee was aware that the SPC for golimumab states that for people who weigh more than 100 kg whose disease does not show an adequate clinical response after three or four doses, the dose of golimumab may be increased to 100 mg once a month.
The Committee heard two different opinions about the proportion of people who would be eligible for the higher dose. The Committee agreed that this proportion was uncertain, but that it could be substantial. The Committee noted that the 100 mg dose of golimumab was not considered in the economic model, but that, because of the patient access scheme (as described in section 2.4), the cost of the 100 mg dose would be equal to that of the 50 mg dose. In addition, the Committee acknowledged the comments from the clinical specialists that, in clinical practice, people would be more likely to be switched to a different TNF inhibitor if no response was observed with the 50 mg dose, than to have the dose increased (see section 4.6). The Committee also noted TA199 states that treatment choice should be based on cost (taking into account drug administration costs, required dose and product price per dose), with treatment initiated with the least expensive drug. Therefore the Committee concluded that with the incorporation of the patient access scheme, golimumab would be considered an acceptable option for the treatment of psoriatic arthritis if used as described for other TNF inhibitors in TA199.
4.15
The Committee discussed the discontinuation of treatment with etanercept, infliximab and adalimumab in TA199. The Committee considered that the recommendation to discontinue treatment based on an inadequate PsARC response at 12 weeks included in TA199 was also appropriate for golimumab.
The Committee was aware that no evidence had been provided by the manufacturer for the use of golimumab after the failure of other TNF inhibitors.
The Committee was therefore unable to make recommendations about the use of golimumab following the failure of other TNF inhibitors.
4.16
The Committee was aware that there may be some circumstances that could affect a person's responses to components of the PsARC such as any physical, sensory or learning disabilities, or communication difficulties. The Committee concluded that in such cases, healthcare professionals should make any adjustments they consider appropriate.
4.17
The Committee was aware of registries that collect data on the long-term outcomes of treatment with TNF inhibitors for rheumatoid arthritis. The
Committee noted the importance of registries in gathering data and supported the inclusion of outcomes specific to psoriatic arthritis in a suitable registry so that specific information about treatments and treatment-related adverse events in psoriatic arthritis can be collected.
4.18
In summary, the Committee considered the clinical and cost effectiveness of golimumab in the light of the submitted evidence and the comments of the clinical specialists, the commissioning expert and the patient expert. The
Committee noted that although the evidence suggested that golimumab may be Golimumab for the treatment of psoriatic arthritis (TA220) less effective in its anti-arthritic activity (based on the HAQ score results from the mixed treatment comparison and the data for radiographic progression), the evidence was not robust enough to confirm clinically important differences in the effectiveness of golimumab compared with the other TNF inhibitors. The
Committee further noted that golimumab was, in effect, not cost effective when compared with etanercept, but may be cost effective when compared with adalimumab and infliximab. The Committee was aware that the patient access scheme (as described in section 2.4) would provide the 100 mg dose of golimumab at the same cost as the 50 mg dose. The Committee concluded that, with the incorporation of the patient access scheme and if the criteria specified in TA199 were met, golimumab should be recommended as an option for the treatment of active and progressive psoriatic arthritis in adults, as described for other TNF inhibitor treatments in TA199. it is used as described for other tumour necrosis factor (TNF) inhibitor treatments in 'Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis' (NICE technology appraisal guidance 199) and and the manufacturer provides the 100 mg dose of golimumab at the same cost as the 50 mg dose.
Summary of the Appraisal Committee's key conclusions
T
1.1
When using the Psoriatic Arthritis Response Criteria (PsARC; as set out in NICE technology appraisal guidance 199), healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties that could affect a person's responses to components of the PsARC and make any adjustments they consider appropriate.
1.2
Golimumab for the treatment of psoriatic arthritis (TA220)
The key drivers for these recommendations were: 
4.5
The Committee noted there had been no head-to-head trials between golimumab and any of the other TNF inhibitors. As a result, the manufacturer had conducted a mixed treatment comparison. The Committee recognised the limitations of mixed treatment comparisons and was aware that the associated results would need to be interpreted with caution.
4.7
The Committee noted that for PsARC response and absolute change in PASI from baseline, the results of the mixed treatment comparison suggested golimumab was generally equivalent to the other TNF inhibitors. However, the Committee also noted that golimumab had the lowest HAQ score change from baseline compared with the other TNF inhibitors.
4.8
The Committee was concerned that, out of the four TNF inhibitors that were compared, golimumab had the lowest HAQ score change from baseline and that this might indicate inferiority of its anti-arthritic activity; however, the Committee was also aware of the limitations of the mixed treatment comparison methodology. With regard to the data for radiographic progression, no mixed treatment comparison had been provided. Using a raw comparison of data from separate trials, the Committee understood that absolute differences between golimumab and infliximab in the respective change from baseline in vdH-S score were small, and may be due to differences in the trial populations.
4.9
Relevance to general clinical practice in the NHS Clinical specialists stated that they would be more likely to select a different TNF inhibitor than to increase the dose if the 50 mg dose of golimumab failed to produce a response.
4.6
Uncertainties generated by the evidence The main clinical trial evidence was derived from a single phase III, randomised controlled study. Because there had been no head-to-head trials between golimumab and any of the other TNF inhibitors, the manufacturer had conducted a mixed treatment comparison.
4.7
Based on a raw comparison of golimumab trial data with that of infliximab, the change from baseline in vdH-S score (which is a measure of radiographic progression) at week 24 for golimumab was less than that for infliximab. The Committee was aware, however, that this difference may be due to differences in the trial populations, as reflected by the difference between the trials in the respective changes from baseline with placebo.
4.9
The 100 mg dose in the pivotal trial was not limited to people weighing over 100 kg, and was therefore not reflective of the population in the marketing authorisation for that dose. The utility formula was derived from the HAQ score change and the PASI response. The HAQ score change had a greater effect on utility than the PASI response did, indicating that the utility benefit was driven more by the reduction in joint symptoms than the reduction in skin disease. The Committee concluded that this was appropriate.
4.11
Have any potential significant and substantial health- 
4.13
Golimumab for the treatment of psoriatic arthritis (TA220) When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraph above. This means that, if a patient has psoriatic arthritis and the doctor responsible for their care thinks that golimumab is the right treatment, it should be available for use, in line with NICE's recommendations.
5.3
NICE has developed tools to help organisations put this guidance into practice (listed below).
A costing statement explaining the resource impact of this guidance.
Audit support for monitoring local practice.
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